edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Cantargia
Edison Investment Research has terminated coverage on Cantargia (CANTA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in a Phase IIa clinical trial, CANFOUR, in solid tumours focusing on NSCLC and pancreatic cancer. Cantargia is also preparing to initiate a trial in the US.
In this video, the company’s chief executive officer Göran Forsberg provides an overview of R&D progress, including a summary of the recently reported interim clinical trial results and expected newsflow.
Get access to the very latest content matched to your personal investment style.